prof dr.zeki kiliÇaslan istanbul university faculty of medicine, chest depertament
DESCRIPTION
Treatment with Tumor Necrosis Factor-Alpha (TNF- α ) Antagonists Turkey’s Experience. Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament. Treatment of Latent TB in Anti-TNF-Alpha Therapy Preparing a guideline-1. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/1.jpg)
Prof Dr.Zeki KILIÇASLAN
Istanbul UniversityFaculty of Medicine, Chest Depertament.
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) Antagonists
Turkey’s Experience
![Page 2: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/2.jpg)
Treatment of Latent TB in Anti-TNF-Alpha TherapyPreparing a guideline-1
Attempts to reduce TB risk started in 2002,just after TNF-Alpha antagonists entered into use
The meeting of The Society for Resarch and Education in Rheumatology( SRER). Istanbul. March 2002 .
![Page 3: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/3.jpg)
Direskeneli H, Kılıçaslan Z, İnanç M, et al: Evaluation of patients fortuberculosis prior to treatment with anti-tumor necrosis factor- biological agents. Marmara Medical Journal 2002;15:273-6.
For treatment of Latent TB, the cut-off diameter of PPD is recommended to be≥ 10 mm
Treatment of Latent TB in Anti-TNF-Alpha TherapyPreparing a guideline-1
![Page 4: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/4.jpg)
Second meeting of SRER, May 2005. Izmir
Rheumatologists and Chest Specialists.
Second meeting of SRER 7 May 2005 / İzmir
ParticipantsN. Akkoç, O. Aydıntuğ, A. Cefle, N. Çakır, V. Çobankara, L. Çöplü,
A. Dinç, H. Direskeneli, E. Doğanavşargil, E. Erken, İ. Ertenli, İ. Fresko, B. Göker, A. Gül, V. Hamuryudan, Ş. Haznedaroğlu, A. Işık, M. İnanç,
Y. Karaaslan, G. Keser, S. Kirazlı, C. Korkmaz, F. Oksel, F. Önen, G. Öngen, M. Özhan, Ş. Özkara, S. Pay, T. Pırıldar, T. Şentürk,
E. Terzioğlu, E. Tunç, R. Tunç, E.S. Uçan, Ş. Yavuz, H. Yazıcı, E. Yücel
Those who prepared consensus report: G. Keser, H. Direskeneli, N. Akkoç, M. İnanç, Ş. Özkara, G. Öngen,
A. Gül, E.S. Uçan, İ. Ertenli, H. Yazıcı, E. Doğanavşargil
Treatment of Latent TB in Anti-TNF-Alpha TherapyPreparing a guideline-1
![Page 5: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/5.jpg)
• Around 3000 patients have used anti-TNF treatment 13 of 2000 patients were diagnosed TB. 6 cases were not evaluated for latent TB
1 case did not use adviced INH treatment
6 cases were not recommended to use INH because of their PPD <10mm
There is no TB case among users of prophilactic treatment according to 2002 guideline.
2nd SRER censensus report 7 May 2005 / İzmir
Treatment of Latent TB in Anti-TNF-Alpha TherapyPreparing a guideline-2005
![Page 6: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/6.jpg)
Cases recommended INH treatment;
•Chest x-ray is normal and TST is positive( ≥5 mm )
•Cases have suspected fibrocalcified lesions.
•Close contacts with TB patients last one year.
•Health workers having high TB risk.
Treatment of Latent TB in Anti-TNF-Alpha TherapyPreparing a guideline-2005
2nd SRER censensus report 7 May 2005 / İzmir
![Page 7: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/7.jpg)
5 Medical centers
(Medical Faculty of İstanbul, Medical Faculty of Cerrahpaşa , Medical faculty of Çukurova ,Medical Faculty of G.Antep , Medical Faculty ofAnkara )
The evaluations of 1319 cases.
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
![Page 8: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/8.jpg)
Total case; 1319
Female: 53.2 % Male: 46.8 %
Mean age : 39.2- 41.2
Mean follow-up period: 5.9 months- 15.8 months
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 9: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/9.jpg)
Rheumatologic diseases (n; 1204 );
Rheumatoid Artrit: 469 (39% )
SA: 446 (37 %)
Diğer: 289 (24% )
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 10: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/10.jpg)
Anti-TNF-Alpha Drugs ( n; 1156 )
Infliximab 475 (41.1 %)
Etanercept 537 (46.4%)
Adalimumab 144 (12.5 %)
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 11: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/11.jpg)
BCG state (n:886 ):
Vaccination ratio : 83. 7 % (%72.2- % 89.1)
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 12: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/12.jpg)
Abnormal chest x-ray on initial screening
Ankara % 11.6
Cerrahpaşa % 12.1
İstanbul % 45.8 (? )
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 13: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/13.jpg)
TST Results (n:1101 )
≥5 mm ; 618 ( % 56.1 )< 5 mm ; 483 (% 43.9)
Mean TST diameter : 7.53 mm (n:484)
Mean TST diameter :10.3 mm (n:115)
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 14: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/14.jpg)
TST Results (n:1101 )
The booster effect
TST negative(< 5 mm)number: 410 (2 center)
Booster test number : 271 (% 66.1)
Booster effect (+) : 24 (% 8.1)
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 15: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/15.jpg)
Cases given INH chemoprophylaxis
Mean : % 69.9
Range: % 64- % 82.7 *
* Istanbul Faculty of Medicine
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 16: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/16.jpg)
INH Toxicity
Drug interrupted ; % 5.9 (28/484)
Drug stopped : % 0.4 (2/484)
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 17: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/17.jpg)
TB diagnosed cases
8/1319 : % 0.6
Pulmonary TB: 6
Extra pulmonary TB: 2
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 18: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/18.jpg)
• 8 TB Cases• 4 cases ( % 0.3, 4/1319) appeared despite following the guideline (3 cases had not prophylaxis indication + 1 case used INH )
Treatment with Tumor Necrosis Factor-Alpha (TNF-α) AntagonistsTurkey’s Experience for TB
Çağatay T et al. Turkish Thoracic S. Congres-2008Zuhur F et al. Turkish Thracic S. Congres-2007Hanta I et al. Clinical Rheumatology 2008Elbek O et al Turkish Thoracic S. Congres-2007Yalçın A et al Turkish Thoracic S. Congres-2007
![Page 19: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/19.jpg)
Increase in TB risk with TNF-alpha antagonists
USA: 4 times (1) Sweden: 2 times (2)
In a global study, TB risk was found 0.11-0.24 %in 10.000 RA patients (3)
In USA it was % 0.02 per 100 patient-years in 55.000 RA patients.(3)
The treatment with TNF-alpha antagonists and Tuberculosis.
(3) M.H. Schiff,Ann. Rheum. Dis. 65 (2006) 889–894.
(1)F. Wolfe, Arthritis Rheum. 50 (2004) 372–379.
(2)J. Askling, Arthritis Rheum. 52 (2005) 1986–1992.
![Page 20: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/20.jpg)
Results;
There is a 10 times increase in TB risk even when the guideline is applied.
The use of IGRA’s testsinstead of TST should be discussed.
The treatment with TNF-alfa antagonists and Tuberculosis.
![Page 21: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/21.jpg)
Risk of cancer in Turkish patients after treatment with TNF antagonists
26 Rheumatology centers.
2199 patient(1247 female, 952 Male) Mean age : 41.8 years
943 AS , 931 RA, 132 PsA, 127 JCA, 66 Other
Etanercept 923 (1028.54 patient-year)İnfliximab 853 (1014.68 patient-year)Adalimumab 259 (223.69 patient-year)More than one 164
The treatment with TNF-alfa antagonists and Cancers.
![Page 22: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/22.jpg)
![Page 23: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/23.jpg)
This nationwide survey did not show an increased risk of cancer associated with TNF antagonist use when data with three drugs were considered together
On the other hand, there was an increase of cancer risk with etanercept use when these agents were considered separately and this trend was also present among RA patients taken as a separate group.
The treatment with TNF-alfa antagonists and Cancers.
![Page 24: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/24.jpg)
Preliminary presentation of 70 cases.
If we use the Quantiferon –TB Gold Test as a gold standart;
The value of TST for diagnosis of Latent TB ;
5 mm and above 10 mm and aboveSensitivity: % 72 % 63 Specificity: % 56 % 70
There is a weak concordance (Kappa: 0.27)
TST and Quantiferon-TB Test for diagnosis of latent TB infection ?
Tülin ÇAĞATAY at .Turkish Thracic S. Congres-2008
![Page 25: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/25.jpg)
Preliminary presentation of 70 cases.
BCG effect;
11 out of 70 patients “indeterrminate result” (all BCG vaccinated)
In 48 BCG vaccinated patients :
The sensitivity of TST test (≥ 5 mm) for latent TB was 50 %
Tülin ÇAĞATAY et al. Turkish Thracic S. Congres-2008
TST and Quantiferon-TB Test for diagnosis of latent TB infection ?
![Page 26: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/26.jpg)
Tülin ÇAĞATAY et al.Turkish Thracic S. Congres-2008
TST enduration diameters were compared before and after treatment in 182 cases treated with TNF-α Antagonists.
1st TST 2nd TST
6.60 ± 0.51’ mm 15±0.55 (p<0.001) mm
Does Anti TNF-Alfa treatment change TST response ?
![Page 27: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/27.jpg)
In 26 out of 87 first TST- negative cases (29.8 %)second TST turned to positive ( ≥ 5 mm)
In logistic regression analysis, no independent variable affecting TST diameter increase was found but the use of TNF-Alpha antagonists
Tülin ÇAĞATAY et al.Turkish Thracic S. Congres-2008
Does Anti TNF-Alfa treatment change TST response ?
![Page 28: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/28.jpg)
Is it necessary to repeat TST among first TST- negative cases after one year treatment ?
Tülin ÇAĞATAY et al.Turkish Thracic S. Congres-2008
Does Anti TNF-Alfa treatment change TST response ?
![Page 29: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/29.jpg)
N. Inanc · H. Direskeneli . Rheumatol Int (2006) 27:67–71
Anti TNF-Alfa treatment and other serious infections
130 RA patients treated with DMARDs and 48 RA patients treated with TNF-Alpha antagonists were compared.
![Page 30: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/30.jpg)
N. Inanc · H. Direskeneli . Rheumatol Int (2006) 27:67–71
Anti TNF-Alfa treatment and other serious infections
![Page 31: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/31.jpg)
N. Inanc · H. Direskeneli . Rheumatol Int (2006) 27:67–71
Anti TNF-Alfa treatment and other serious infections
![Page 32: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/32.jpg)
Anti TNF-Alfa treatmentTurkey’s experience
Evaluation of these cases became a heavy burden for the chest clinics of major hospitals.
More specific organizations can be needed for registration and follow-up purposesbecause of rapid increase in Anti TNF-
Alfa treatment.
Result
![Page 33: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/33.jpg)
THANK YOU
![Page 34: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/34.jpg)
the estimated rate of TB among RA patients treatedwith INF in the US was 24.4 cases per 100,000, compared to abackground TB in RA patients of 6.2 cases per 100,000 peryear in US [89]. F. Wolfe, K. Michaud, J. Anderson, K. Urbansky, Tuberculosisinfection in patients with rheumatoid arthritis and the effectof infliximab therapy, Arthritis Rheum. 50 (2004) 372–379.
In global clinical trial data released by Abbott pharmaceuticalsin N10,000 RA patients, all of whom were screenedfor latent TB, the event rate of TB per 100 patient-yearswas 0.24 in longstanding RA (N3 years) and 0.11 per 100patient-years in early RA [91].
![Page 35: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/35.jpg)
In an analysis of the USpostmarketing safety of ADA from Abbott-supported trialsfrom 2002 to 2004 of pre-screened patients with anestimated 55,384 patients years of exposure, 11 patientswere reported to have TB, yielding a rate of 0.02 per 100patient-years [91]. Three of the eleven (27%) had extrapulmonaryTB
![Page 36: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/36.jpg)
The relative risk of TB in RA patients on anti-TNF therapycompared to a control RA group not treated with TNFαantagonists was 4.0 (95% CI: 1.3–12). The calculated relativerisk of TB in the control RA population compared to thegeneral Swedish population was 2.0 (95% CI 1.2–3.4)
![Page 37: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/37.jpg)
A Spanish study evaluated the effectiveness ofrecommendations set forth to prevent reactivation of latentTB in patients treated with TNFα antagonists [95]. Rates ofactive TB after implementation of the recommendationsdecreased by 78% (incidence risk ratio 0.22, 95% CI: 0.03–0.88, p=0.008), highlighting the effectiveness of their implementedstrategies.The importance of TB prevention recommendations washighlighted in a recent report from the BIOBADASER registry,which evaluated new cases of active TB in 5198 patientstreated with TNF antagonists after the dissemination ofrecommendations to prevent reactivation of latent TBinfection [94]. Fifteen active TB cases were noted (rate172 per 100,000 patient-years, 95% CI 103–285). Theprobability of developing active TB was 7 times higherwhen recommendations were not followed.
![Page 38: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/38.jpg)
Also, the FDA recentlyapproved QuantiFERON-TB Gold test, which measuresinterferon-γ production after 16–24 h incubation ofwhole blood with synthetic peptides [96].
![Page 39: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/39.jpg)
![Page 40: Prof Dr.Zeki KILIÇASLAN Istanbul University Faculty of Medicine, Chest Depertament](https://reader030.vdocuments.mx/reader030/viewer/2022012910/56814411550346895db0afa1/html5/thumbnails/40.jpg)
SONUÇ